Samarium-153-EDTMP (Quadramet(®)) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial

PSA-TRICOM is a therapeutic vaccine in late stage clinical testing in metastatic castration-resistant prostate cancer (mCRPC). Samarium-153-ethylene diamine tetramethylene phosphonate (Sm-153-EDTMP; Quadramet(®)), a radiopharmaceutical, binds osteoblastic bone lesions and emits beta particles causin...

Descripción completa

Detalles Bibliográficos
Autores principales: Heery, Christopher R., Madan, Ravi A., Stein, Mark N., Stadler, Walter M., Di Paola, Robert S., Rauckhorst, Myrna, Steinberg, Seth M., Marté, Jennifer L., Chen, Clara C., Grenga, Italia, Donahue, Renee N., Jochems, Caroline, Dahut, William L., Schlom, Jeffrey, Gulley, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340090/
https://www.ncbi.nlm.nih.gov/pubmed/27486817
http://dx.doi.org/10.18632/oncotarget.10883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340090/
https://www.ncbi.nlm.nih.gov/pubmed/27486817
http://dx.doi.org/10.18632/oncotarget.10883

Ejemplares similares